Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arbutus Biopharma advances promising drug candidates and secures financial stability

Arbutus Biopharma showcased progress in its drug development pipeline, particularly with positive Phase IIa trial results for AB-729 and the introduction of AB-343 as a promising oral coronavirus drug candidate. The company's financial stability and strategic focus on upcoming milestones position it well for future growth.

Arbutus Biopharma advances HBV and COVID-19 treatments with strong finances

Arbutus Biopharma is making significant progress in developing treatments for HBV and COVID-19, supported by a strong financial position.
While facing challenges such as FDA clinical holds and trial planning, the company is well-positioned to capitalize on upcoming opportunities.
Strategic focus on clinical advancements, financial stability, and future growth opportunities defines Arbutus Biopharma's outlook for 2023.

Arbutus Biopharma advances Hepatitis B cure development amid financial strength

Arbutus Biopharma is progressing well in its quest for a functional cure for chronic Hepatitis B, supported by a strong pipeline and financial stability.
The company faces challenges in navigating development hurdles and competition but has opportunities to lead in innovative therapies for HBV and COVID-19.
By focusing on key milestones, strategic trial designs, and effective resource management, Arbutus aims to drive growth and success in the biopharmaceutical sector.

Arbutus Biopharma focuses on HBV cure amid leadership transition

Arbutus Biopharma's strategic focus on developing a functional cure for chronic HBV and maintaining financial stability through 2026 positions the company for future growth.
While workforce reduction and legal challenges present hurdles, the company's pipeline progress and leadership transition signal resilience and adaptability.
Opportunities in pipeline expansion, partnerships, and clinical trial advancements underscore Arbutus Biopharma's potential for long-term success in the biopharmaceutical industry.

Arbutus Biopharma focuses on HBV cure, extends cash runway

Arbutus Biopharma's Q4 2023 earnings call highlighted a strategic focus on HBV and extending cash runway. Progress in clinical trials and ongoing litigation efforts against key players. Anticipating reduced cash burn in 2024 for financial sustainability.

Arbutus Biopharma reports strong financials and progresses HBV treatment pipeline

Arbutus Biopharma showcased a strong financial position and positive results in Phase 1a study of AB-836.
The company's focus on developing a functional cure for chronic HBV and advancing pipeline assets demonstrates commitment to innovation.
While facing questions on dosing strategies and trial designs, Arbutus sees opportunities in upcoming data releases and advancing clinical studies.

Arbutus Biopharma reports promising HBV trial results and financial strength

Arbutus Biopharma demonstrates positive trial results and financial stability, positioning the company well for future growth and innovation in HBV treatment
Challenges in trial design, data interpretation, and legal proceedings require careful navigation to capitalize on opportunities for advancement
Opportunities lie in further data reporting, biomarker exploration, and potential partnerships to drive progress towards a functional cure for chronic hepatitis B

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial that has been expanded to include a PD-1 monoclonal antibody, nivolumab.

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that preliminary data from its on-going Phase 2a clinical trial evaluating the safety, tolerability and antiviral activity of the combination of AB-729, the Company's lead RNAi therapeutic, and pegylated interferon alfa-2a (IFN) in patients with chronic hepatitis B virus (cHBV) was presented today at the European Association for the Study of the Liver (EASL) Congress.

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2023 taking place June 21 - 24, 2023 in Vienna, Austria.

Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023

WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at the Jefferies Healthcare Conference taking place in New York on Wednesday, June 7, 2023 at 9:30 am ET.

Arbutus to Present at Jefferies Healthcare Conference

Preliminary results from phase 2a study, using AB-729 + Nucleoside analogue + PEG-IFN-2a for the treatment of patients with Hepatitis B, are expected in Q2 of 2023. Results from phase 2a study, using AB-729 + Nucleoside analogue + VTP-300, for the treatment of patients with Hepatitis B, are expected in the 2nd half of 2023.

Arbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023

NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arbutus (ABUS) Upgraded to Buy: Here's Why

WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in a fireside chat at the JMP Securities Life Sciences Conference taking place in New York on Tuesday, May 16, 2023 at 9:00 am ET.

Arbutus to Present at JMP Securities Life Sciences Conference

Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q1 2023 Results Conference Call May 4, 2023 8:45 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO and CAO Karen Sims - VP of Clinical Development Michael Sofia - Chief Scientific Officer Conference Call Participants Thomas Yip - H.C. Wainwright Roy Buchanan - JMP Dennis Ding - Jefferies Operator Good day, and thank you for standing by.

Arbutus Biopharma Corporation (ABUS) Q1 2023 Earnings Call Transcript

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.11 per share a year ago.

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post-  AB-729 treatment

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that its investigational new drug application for its novel, oral PD-L1 inhibitor AB-101 for hepatitis B has been put on a clinical hold by the US Food and Drug Administration (FDA). The company said AB-101 was designed to “reawaken and boost” the immune system of chronic hepatitis B patients and believes that, when used in combination with other approved therapies, could potentially lead to a functional cure in hepatitis B patients.

Arbutus Biopharma clinical hold slows hepatitis B momentum: broker

The FDA has placed a clinical hold on AB-101, Arbutus' experimental chronic hepatitis B virus therapy. Arbutus had hoped to advance AB-101 into early-stage testing and report initial data on it later this year.

Why Arbutus Biopharma Stock Is Sinking Today

WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company was notified via verbal communication from the U.S. Food and Drug Administration (FDA) that the AB-101 Investigational New Drug (IND) application has been placed on clinical hold. AB-101 is a novel, oral PD-L1 inhibitor designed to reawaken and boost the immune system of patients with chronic hepatitis B virus (cHBV). The FDA indicated they will provide an official Clinical Hold letter to Arbutus within 30 days. Based on this communication, the Company no longer intends to report initial data from the single-ascending dose portion of the Phase 1 clinical trial in the second half of 2023.

Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor

WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its first quarter 2023 financial results and corporate update for Thursday, May 4, 2023. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update

Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted as late-breaker oral presentations at the Global Hepatitis Summit 2023 taking place April 25-28, 2023, in Paris.

Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023

Companies seek compensation for Pfizer's and BioNTech's unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech

Initial data expected in the second half of 2023

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q4 2022 Earnings Conference Call March 2, 2023 8:45 AM ET Company Participants Lisa Caperelli - VP of IR William Collier - President and CEI Michael Sofia - Chief Scientific Officer David Hastings - CFO Michael McElhaugh - COO Conference Call Participants Dennis Ding - Jefferies Charles Moore - Baird Thomas Yip - H.C. Wainwright Keay Nakae - Chardan Roy Buchanan - JMP Securities Operator Good day, and thank you for standing by.

Arbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Call Transcript

Significant progress made advancing proprietary programs in chronic HBV and Coronavirus

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2022 financial results and corporate update for Thursday, March 2, 2023. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following three upcoming investor conferences:

Arbutus to Participate in Three Upcoming Investor Conferences

WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified the Company of her intention to resign from the Company's Board of Directors, effective February 26, 2023. Dr. Tran will be transitioning into public service commencing February 27, 2023, that will preclude her participation on the Arbutus and other pharmaceutical and biotechnology Boards.

News for Arbutus Biopharma Stock (ABUS)